(i) the voting rights of any relevant securities under any option; or 
  (ii) the voting rights or future acquisition or disposal of any relevant securities to which 
  any derivative is referenced: 
  If there are no such agreements, arrangements or understandings, state "none" 
----------------------------------------------------------------------------------------------- 
 
  None 
----------------------------------------------------------------------------------------------- 
 
   (c)        Attachments 
 
 Is a Supplemental Form 8 (Open Positions) attached? 
                                                        NO 
----------------------------------------------------  ---- 
 
 
 Date of disclosure: 
                         19-December-2011 
---------------------  ------------------ 
 Contact name: 
                         Chetan Shah 
---------------------  ------------------ 
 
 Telephone number:       020 3395 6564 
---------------------  ------------------

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RETDKCDQBBDDDBD

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma